Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,326 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75 - NCT05430399RecruitingPhase 3
Utidelone vs docetaxel for HER2-negative breast cancer
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Guangzhou, GangdongAges 18 years+ - NCT06797037Recruiting
Nurse-led support for cancer patients on oral treatment
This trial tests a program where an advanced practice nurse coordinates your care while you take oral cancer medication at home. You might benefit if you want extra check-ins by phone and are comfortable with two nurse visits at home over six months.
ToulouseAges 18 years+ - NCT07216105RecruitingPhase 1
FT836 immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy called FT836, given alone or with chemotherapy or other antibodies, for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if it is safe and helps shrink or control tumors.
La Jolla, CaliforniaAges 18 years+ - NCT06855134Recruiting
Genome-guided treatment for advanced rare cancers
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
AugsburgAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT03767075RecruitingPhase 2
Basket trial matching cancer patients to targeted treatments
This trial tests whether matching your tumor’s DNA/RNA results to a specific cancer medicine can work better than standard options when cancer has spread or can’t be removed by surgery. You may be assigned to a “basket” (sub-study) based on the exact changes found in your tumor.
VillejuifAges 18 years+ - NCT07407933RecruitingPhase 1/Phase 2
YL201 with other cancer drugs for advanced solid tumors
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04984551RecruitingPhase 2
Training plus support to improve palliative care for advanced cancer
This trial studies whether a program called Project ECHO can improve the quality of palliative care (comfort-focused care) for people with advanced cancer and their caregivers in underserved areas. It also involves training local health care providers so they can better support patients and families over time.
Houston, TexasAges Any age - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06008288RecruitingPhase 2
JAB-21822 for advanced pancreatic or other solid tumors with KRAS G12C
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
Hefei, AnhuiAges 18 years+ - NCT07128303RecruitingPhase 1
Study of a new drug for advanced solid tumors with a specific genetic feature
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06782334RecruitingPhase 1/Phase 2
AMT-116 for advanced solid tumors
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT06413615RecruitingPhase 2
Study of a new targeted drug for advanced solid tumors with HER2
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT07294664RecruitingPhase 2
Drug combo trial for first treatment of advanced stomach cancer
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
Zhengzhou, HenanAges 18 years+ - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT06770569RecruitingPhase 1
Study of HRS-3802 for advanced solid tumors
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Saint Leonards, New South WalesAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT06072989RecruitingPhase 1
B4T2-001 CAR-T infusions for solid tumors without chemo
This trial tests a new kind of cell therapy called CAR-T that targets a protein called BT-001 on solid tumors. It uses repeat infusions and avoids the strong chemotherapy usually given before treatment, which may be easier to tolerate.
Shanghai, China/ShanghaiAges 18–70 - NCT05772455RecruitingPhase 1
Drug study for adults with solid tumors
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,326 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.